Depression is associated with lower adherence to antihypertensive and lipid-lowering treatment in individuals with type 1 diabetes

被引：0
|
作者：
Lithovius, R. [1 ,2 ,3 ]
Mutter, S. [1 ,2 ,3 ]
Parente, E. B. [1 ,2 ,3 ]
Harjutsalo, V. [1 ,2 ,3 ]
Groop, P. H. [1 ,2 ,3 ]
机构：
[1] Folkhalsan Inst Genet, Helsinki, Finland
[2] Univ Helsinki, Dept Nephrol, Helsinki, Finland
[3] Helsinki Univ Hosp, Helsinki, Finland
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
868
引用
收藏
页码：S446 / S446
页数：1
相关论文
共 50 条
  • [31] New treatment options for lipid-lowering therapy in subjects with type 2 diabetes
    Roberto Scicali
    Antonino Di Pino
    Viviana Ferrara
    Francesca Urbano
    Salvatore Piro
    Agata Maria Rabuazzo
    Francesco Purrello
    Acta Diabetologica, 2018, 55 : 209 - 218
  • [32] Optimisation of quality indicators for lipid-lowering treatment of type 2 diabetes mellitus
    Madsen, Michael Moesmann
    Kaersvang, Lone
    Hansen, Anders Wurgler
    Flink, Morten
    Nielsen, Henning K.
    Hansen, Klaus Wurgler
    DANISH MEDICAL JOURNAL, 2018, 65 (09):
  • [33] New treatment options for lipid-lowering therapy in subjects with type 2 diabetes
    Scicali, Roberto
    Di Pino, Antonino
    Ferrara, Viviana
    Urbano, Francesca
    Piro, Salvatore
    Rabuazzo, Agata Maria
    Purrello, Francesco
    ACTA DIABETOLOGICA, 2018, 55 (03) : 209 - 218
  • [34] Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
    Gulliford, MC
    Charlton, J
    Latinovic, R
    JOURNAL OF HUMAN HYPERTENSION, 2005, 19 (02) : 111 - 117
  • [35] Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
    M C Gulliford
    J Charlton
    R Latinovic
    Journal of Human Hypertension, 2005, 19 : 111 - 117
  • [36] Evidence-Based Adherence Classes for Combination Antihypertensive, Lipid-Lowering, and Antidiabetic Therapy
    Davis, James
    Starr, Ranjani
    Juarez, Deborah T.
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2015, 7 (04) : E108 - E115
  • [37] COST-EFFECTIVENESS OF ADHERENCE-IMPROVING INTERVENTIONS FOR ANTIHYPERTENSIVE AND LIPID-LOWERING MEDICATIONS
    Chapman, R. H.
    Kowal, S.
    Cherry, S. B.
    Ferrufino, C. P.
    Roberts, C. S.
    Chen, L.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 : 49 - 49
  • [38] Impact of rosiglitazone therapy on the lipid profile and lipid-lowering treatment in type 2 diabetes patients
    Sub, D. C.
    Huang, J.
    Nocea, G.
    Gyin, D.
    Krishnaraeah, G.
    VALUE IN HEALTH, 2007, 10 (06) : A231 - A231
  • [39] Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia - Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Whelton, PK
    Barzilay, J
    Cushman, WC
    Davis, BR
    Iiamathi, E
    Kostis, JB
    Leenen, FHH
    Louis, GT
    Margolis, KL
    Mathis, DE
    Moloo, J
    Nwachuku, C
    Panebianco, D
    Parish, DC
    Pressel, S
    Simmons, DL
    Thadani, U
    ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (12) : 1401 - 1409
  • [40] Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes mellitus
    Williams, MR
    Maahs, DM
    McFann, K
    Nadeau, K
    Klingensmith, GJ
    Eckel, RH
    Wadwa, RP
    CIRCULATION, 2006, 113 (08) : E355 - E355
12345